VIR Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.7% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vir Biotechnology, Inc.
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Sector
Healthcare
Industry
Biotechnology